Genedata, a leading provider of in silico solutions for pharmaceutical R&D and related life sciences, today announced its new Japanese website
(www.genedata.jp), which enhances knowledge sharing related to target discovery and integrated biological data management; high throughput screening and high content screening; and biomarker discovery and personalized medicine.
The new Japanese website closely follows an expansion of Genedata in Japan and supports the growing customer base in Asia. Recently signed customers include Astellas Pharmaceuticals, Asubio, Chugai Pharmaceuticals, Takeda Pharmaceuticals, as well as several other pharmaceutical and biotechnology companies. Academic institutions using Genedata software systems include Hyogo College of Medicine, NCC Japan, RIKEN, and Tokyo University. The success in Japan correlates directly with the success of Genedata globally; the majority of the top 50 pharmaceuticals use Genedata software systems for large-scale biology applications to improve R&D efficiency.
“We hope that the new Japanese site facilitates easier access to valuable information for our Japanese customers,” said Dr. Othmar Pfannes, CEO of Genedata. “We’ve recently seen significant growth in Japanese business and are committed to further expanding Genedata’s presence in Japan.”
Genedata transforms data into intelligence with a portfolio of advanced software solutions for drug discovery, industrial biotechnology, and life science research. Used by a majority of the world’s top 50 pharmaceutical companies and leading research organizations, Genedata solutions make research data accessible and understandable, enabling scientific discovery that fights disease and improves health and quality of life worldwide. Founded in 1997, Genedata is headquartered in Switzerland, and has offices in Japan, Germany, and the US. www.genedata.com
Marketing & Communications
Phone: +41 61 511 8459
Phone: +1 508 881 3109
The statements in this press release that relate to future plans, events or performance are forward-looking statements that involve risks and uncertainties, including risks associated with uncertainties related to contract cancellations, developing risks, competitive factors, uncertainties pertaining to customer orders, demand for products and services, development of markets for the Company's products and services. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. The Company undertakes no obligation to release publicly the result of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.
All product and service names mentioned are the trademarks of their respective companies.